Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.

Kidney international - 1 Dec 2021

Bai Yuntao, Kim Ji Young, Bisunke Bijay, Jayne Laura A, Silvaroli Josie A, Balzer Michael S, Gandhi Megha, Huang Kevin M, Sander Veronika, Prosek Jason, Cianciolo Rachel E, Baker Sharyn D, Sparreboom Alex, Jhaveri Kenar D, Susztak Katalin, Bajwa Amandeep, Pabla Navjot Singh

Abstract excerpt

A multitude of disease and therapy related factors drive the frequent development of kidney disorders in cancer patients. Along with chemotherapy, the newer targeted therapeutics can also cause kidney dysfunction through on and off-target mechanisms. Interestingly, among the small molecule inhibitors approved for the treatment of cancers that harbor BRAF-kinase activating mutations, vemurafenib can trigger...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferrochelatase

Share to Indoles

Share to Kidney

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 34534550
DOI: 10.1016/j.kint.2021.08.022
PMCID: PMC8608726

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.PMID 34534550Read ↗

Nephrotoxicity of the BRAF-kinase inhibitor Vemurafenib is driven by off-target Ferrochelatase inhibitionSemantic proximity Read ↗

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.Semantic proximity Read ↗

Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation.Semantic proximity Read ↗

TEAD inhibitor induced switch in energy metabolism drives human podocyte injury in vitroSemantic proximity Read ↗

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.Semantic proximity Read ↗

USP7 inhibitor P5091 enhances the antitumor efficacy of vemurafenib in BRAFV600E-mutant thyroid cancer via ferroptosis.Semantic proximity Read ↗

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.Semantic proximity Read ↗

Critical role of VHL/BICD2/STAT1 axis in crystal-associated kidney diseaseSemantic proximity Read ↗

Binding to Albumin and Off-Target Toxicity Confound the Use of LRRC8/VRAC Channel Blockers in Cell Physiology AssaysSemantic proximity Read ↗

Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.Semantic proximity Read ↗

Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.